Compare WIW & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIW | PGEN |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.9M | 1.5B |
| IPO Year | N/A | N/A |
| Metric | WIW | PGEN |
|---|---|---|
| Price | $8.68 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 229.9K | ★ 4.1M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $8.01 | $0.65 |
| 52 Week High | $9.37 | $5.23 |
| Indicator | WIW | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 48.12 |
| Support Level | $8.67 | $3.42 |
| Resistance Level | $8.73 | $3.75 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 50.00 |
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.